- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Dimensions
-
28 cm
- Extent
-
S. 906 - 1059
- Language
-
Englisch
- Notes
-
Ill., graph. Darst.
Literaturangaben
- Bibliographic citation
-
World journal of urology ; Vol. 33, Nr. 7
- Keyword
-
Prostatakrebs
Krebs
Onkologie
Hoden
Männliches Geschlechtsorgan
Hodensack
Prostata
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Springer
- (when)
-
2015
- Contributor
-
Poel, Henk van der
- Table of contents
- Rights
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Last update
-
11.06.2025, 1:59 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Aufsatzsammlung
Associated
- Poel, Henk van der
- Springer
Time of origin
- 2015
Other Objects (12)
MRI for managing intermediate & low risk prostate cancer
Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
Focal therapy in intermediate- and high-risk prostate cancer
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE)
Improving interMediAte Risk management. MARK study
Advanced management of intermediate-high risk pulmonary embolism
The value of apparent diffusion coefficient values in predicting Gleason grading of low to intermediate-risk prostate cancer
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
MRI for managing intermediate & low risk prostate cancer
Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
Focal therapy in intermediate- and high-risk prostate cancer
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE)
Improving interMediAte Risk management. MARK study
Advanced management of intermediate-high risk pulmonary embolism
The value of apparent diffusion coefficient values in predicting Gleason grading of low to intermediate-risk prostate cancer
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
MRI for managing intermediate & low risk prostate cancer
Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer
PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
Focal therapy in intermediate- and high-risk prostate cancer
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer
Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE)
Improving interMediAte Risk management. MARK study
Advanced management of intermediate-high risk pulmonary embolism
The value of apparent diffusion coefficient values in predicting Gleason grading of low to intermediate-risk prostate cancer
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer